Storia in 3 fonti

Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma

Teclistamab improved PFS, OS in patients who had received up to three previous lines of therapy

Raccontata da

morningstar.com

medpagetoday.com

medicalxpress.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo1 mesi fa

Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma

Teclistamab hit 69.8% 18-month PFS vs 26.9% with standard regimens (HR 0.29) in phase III MajesTEC-9. BCMA bispecifics now displace proteasome inhibitor combos at first relapse, but grade 3–4 infections in 41.6% remain a key adoption barrier.

originale

medicalxpress.com1 mesi fa

Teclistamab extends remission in relapsed myeloma, with 70% progression-free at 18 months

Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a…

Leggi questa versione → originale

morningstar.com1 mesi fa

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as…

J&J's TECVAYLI cut progression risk by 71% and mortality by 40% vs. standard of care in second-line relapsed myeloma (Phase 3 MajesTEC-9), with 65.9% complete response rate. FDA/EMA filings submitted; approval would establish bispecifics as a new second-line standard, displacing current triplet regimens.

Leggi questa versione → originale

Timeline cronologica

venerdì 29 maggio 2026·morningstar.com
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple…
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
venerdì 29 maggio 2026·medpagetoday.com
Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma
Teclistamab improved PFS, OS in patients who had received up to three previous lines of therapy
venerdì 29 maggio 2026·medicalxpress.com
Teclistamab extends remission in relapsed myeloma, with 70% progression-free at 18 months
Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard…

Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma

Teclistamab extends remission in relapsed myeloma, with 70% progression-free at 18 months

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as…

Timeline cronologica

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple…

Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma

Teclistamab extends remission in relapsed myeloma, with 70% progression-free at 18 months

Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma

Teclistamab extends remission in relapsed myeloma, with 70% progression-free at 18 months

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as…

Timeline cronologica

New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple…

Bispecific Antibody Boosts Survival in Relapsed/Refractory Multiple Myeloma

Teclistamab extends remission in relapsed myeloma, with 70% progression-free at 18 months